Shopping Cart
Remove All
Your shopping cart is currently empty
Anti-Siglec-2/CD22 Antibody (1M79)
😃Good
Catalog No. TMAY-02165
Alias SIGLEC-2, SIGLEC2, CD22 molecule
Anti-Siglec-2/CD22 Antibody (1M79) is a Mouse antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1M79) can be used in FCM.
Anti-Siglec-2/CD22 Antibody (1M79)
Anti-Siglec-2/CD22 Antibody (1M79)
😃Good
Catalog No. TMAY-02165Alias SIGLEC-2, SIGLEC2, CD22 molecule
Anti-Siglec-2/CD22 Antibody (1M79) is a Mouse antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1M79) can be used in FCM.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 μL | $198 | 7-10 days | 7-10 days |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Anti-Siglec-2/CD22 Antibody (1M79) is a Mouse antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1M79) can be used in FCM. |
| Synonyms | SIGLEC-2, SIGLEC2, CD22 molecule |
| Ig Type | Mouse IgG1 |
| Clone | 1M79 |
| Reactivity | Human |
| Specificity | Human Siglec-2/CD22 |
| Verified Activity | Flow cytometric analysis of Human CD22 expression on human whole blood lymphocytes. Cells were stained with purified anti-Human CD22, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
| Application | |
| Recommended Dose | FCM: 1:25-1:100 |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD22 / Siglec-2 (rh CD22 / Siglec-2; TMPY-02034; P20273-1; Met1-Arg687). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS with 10% Trehalose, pH7.0 |
| Research Background | CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | Unconjugated |
| Others Formats | PerCP/FITC/PE |
| Antibody Types Available | 4 |
| Immunogen | Recombinant Protein: Human CD22 / Siglec-2 Protein (TMPY-02034) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Anti-Siglec-2/CD22 Antibody (1M79) | purchase Anti-Siglec-2/CD22 Antibody (1M79) | Anti-Siglec-2/CD22 Antibody (1M79) cost | order Anti-Siglec-2/CD22 Antibody (1M79)
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.